These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 38194773)

  • 21. Construction of Peptide-Drug Conjugates for Selective Targeting of Malignant Tumor Cells.
    Vrettos EI; Tzakos AG
    Methods Mol Biol; 2021; 2207():327-338. PubMed ID: 33113145
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Recent Progress of pH-Responsive Peptides, Polypeptides, and Their Supramolecular Assemblies for Biomedical Applications.
    Hou M; Liu S
    Biomacromolecules; 2024 Sep; 25(9):5402-5416. PubMed ID: 39105715
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Peptide-drug conjugates as effective prodrug strategies for targeted delivery.
    Wang Y; Cheetham AG; Angacian G; Su H; Xie L; Cui H
    Adv Drug Deliv Rev; 2017 Feb; 110-111():112-126. PubMed ID: 27370248
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Peptide-Drug Conjugates: A New Hope for Cancer Management.
    Chavda VP; Solanki HK; Davidson M; Apostolopoulos V; Bojarska J
    Molecules; 2022 Oct; 27(21):. PubMed ID: 36364057
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A Brief Guide to Preparing a Peptide-Drug Conjugate.
    Bugatti K
    Chembiochem; 2023 Sep; 24(17):e202300254. PubMed ID: 37288718
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Advancement and Strategies for the Development of Peptide-drug Conjugates: Pharmacokinetic Modulation, Role and Clinical Evidence against Cancer Management.
    Malviya R; Verma S; Sundram S
    Curr Cancer Drug Targets; 2022; 22(4):286-311. PubMed ID: 34792003
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Peptide-Drug Conjugates: Design, Chemistry, and Drug Delivery System as a Novel Cancer Theranostic.
    Rizvi SFA; Zhang L; Zhang H; Fang Q
    ACS Pharmacol Transl Sci; 2024 Feb; 7(2):309-334. PubMed ID: 38357281
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Antibody-drug conjugates as targeted therapies: Are we there yet? A critical review of the current clinical landscape.
    Tarcsa E; Guffroy MR; Falahatpisheh H; Phipps C; Kalvass JC
    Drug Discov Today Technol; 2020 Dec; 37():13-22. PubMed ID: 34895651
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Novel Chemical Linkers for Next-generation Antibody-drug Conjugates(ADCs)].
    Tsuchikama K
    Yakugaku Zasshi; 2019; 139(2):209-219. PubMed ID: 30713230
    [TBL] [Abstract][Full Text] [Related]  

  • 30. On the design principles of peptide-drug conjugates for targeted drug delivery to the malignant tumor site.
    Vrettos EI; Mező G; Tzakos AG
    Beilstein J Org Chem; 2018; 14():930-954. PubMed ID: 29765474
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Recent advances in the construction of antibody-drug conjugates.
    Chudasama V; Maruani A; Caddick S
    Nat Chem; 2016 Feb; 8(2):114-9. PubMed ID: 26791893
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Implementing antibody-drug conjugates (ADCs) in HER2-positive breast cancer: state of the art and future directions.
    Ferraro E; Drago JZ; Modi S
    Breast Cancer Res; 2021 Aug; 23(1):84. PubMed ID: 34380530
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pharmacokinetic Considerations for Antibody-Drug Conjugates against Cancer.
    Malik P; Phipps C; Edginton A; Blay J
    Pharm Res; 2017 Dec; 34(12):2579-2595. PubMed ID: 28924691
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Drug conjugates for the treatment of lung cancer: from drug discovery to clinical practice.
    Zhou L; Lu Y; Liu W; Wang S; Wang L; Zheng P; Zi G; Liu H; Liu W; Wei S
    Exp Hematol Oncol; 2024 Mar; 13(1):26. PubMed ID: 38429828
    [TBL] [Abstract][Full Text] [Related]  

  • 35. PDCdb: the biological activity and pharmaceutical information of peptide-drug conjugate (PDC).
    Sun X; Li H; Chen Z; Zhang Y; Wei Z; Xu H; Liao Y; Jiang W; Ge Y; Zheng L; Li T; Wu Y; Luo M; Fang L; Dong X; Xiao M; Han L; Jia Q; Zhu F
    Nucleic Acids Res; 2024 Oct; ():. PubMed ID: 39360619
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Engineering peptide drug therapeutics through chemical conjugation and implication in clinics.
    Rizvi SFA; Zhang H; Fang Q
    Med Res Rev; 2024 Nov; 44(6):2420-2471. PubMed ID: 38704826
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Site-specific antibody drug conjugates for cancer therapy.
    Panowski S; Bhakta S; Raab H; Polakis P; Junutula JR
    MAbs; 2014; 6(1):34-45. PubMed ID: 24423619
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Antibody-Drug Conjugates: A Review on the Epitome of Targeted Anti- Cancer Therapy.
    Hasan M; Alam S; Poddar SK
    Curr Clin Pharmacol; 2018; 13(4):236-251. PubMed ID: 30073930
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Legumain/pH dual-responsive lytic peptide-paclitaxel conjugate for synergistic cancer therapy.
    Zheng S; Cai Y; Hong Y; Gong Y; Gao L; Li Q; Li L; Sun X
    Drug Deliv; 2022 Dec; 29(1):1764-1775. PubMed ID: 35638851
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Smart glypican-3-targeting peptide-chlorin e6 conjugates for targeted photodynamic therapy of hepatocellular carcinoma.
    Fang Y; Ma H; Zhang X; Zhang P; Li Y; He S; Sheng C; Dong G
    Eur J Med Chem; 2024 Jan; 264():116047. PubMed ID: 38118394
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.